IP Library Granted Patent US 8,399,632
Granted Patent B2
US 8,399,632 · App. 12/037,735 · Granted Mar 19, 2013

Method for the purification of recombinant blood coagulation factor IX enriched in sulfated and/or phosphorylated molecules

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,399,632
App. No.
12/037,735
Granted
Mar 19, 2013
Kind
B2
Abstract

The present invention relates to a method for the purification of rFIX using anion exchange chromatography in the pseudo-affinity mode, wherein said method comprises a wash step with a wash buffer having a salt concentration of more than 200 mM. The purification according to the invention provides a method to enrich rFIX molecules which have been posttranslationally modified by sulfation and/or phosphorylation. The present invention further relates to purified rFIX compositions enriched in monosulfated and/or monophosphorylated rFIX molecules.

Claims (25)

1. A method for purification of a recombinant Factor IX (rFIX) composition enriched in monosulfated and/or monophosphorylated rFIX, wherein the method comprises the steps of:

a) loading a composition comprising rFIX onto an anion exchange material;

b) washing the anion exchange material using a high salt wash buffer having a conductivity of 22±1 mS/cm at 25° C., thereby forming a high salt wash buffer fraction comprising rFIX, wherein less than 30% of the rFIX in the high salt wash buffer fraction is monosulfated and/or monophosphorylated;

c) eluting rFIX from the anion exchange material using a gradient of anions in an elution buffer comprising divalent cations;

d) collecting the rFIX eluate in fractions; and

e) pooling fractions enriched in monosulfated and/or monophosphorylated rFIX, thereby forming a purified rFIX composition enriched in monosulfated and/or monophosphorylated rFIX,

wherein at least 30% of the rFIX in the purified rFIX composition are monosulfated and/or monophosphorylated.

2. The method according to claim 1 , wherein the rFIX is human rFIX.

3. The method of claim 1 , wherein the gradient is linear.

4. The method of claim 1 , wherein the gradient is stepwise.

5. The method of claim 1 , wherein the divalent cation is selected from the group consisting of Ca 2+ , Mg 2+ , Sr 2+ , Co 2+ , Ni 2+ , and Zn 2+ .

6. The method of claim 1 , wherein the concentration of divalent cations is from 0.5 mM to 10 mM.

7. The method of claim 6 wherein the concentration of divalent cations is from 2 mM to 5 mM.

8. The method of claim 6 , wherein the concentration of divalent cations is 2 mM.

9. The method of claim 1 , wherein the elution buffer contains a buffering agent selected from the group consisting of Tris, HEPES, Imidazole, Histidine, Phosphate, and MOPS.

10. The method of claim 1 , wherein at the beginning of the gradient the elution buffer has a conductivity of from 0.5 to 16 mS/cm at 25° C. and at the end of the gradient the elution buffer has a conductivity of from 80 to 160 mS/cm at 25° C.

11. The method of claim 1 , wherein at the beginning of the gradient the elution buffer has a conductivity of 2.11 mS/cm at 25° C. and at the end of the gradient the elution buffer has a conductivity of more than 18.6 mS/cm at 25° C.

12. The method of claim 1 , wherein at the end of the gradient, the elution buffer comprises sodium chloride in an amount from 150 mM to 2000 mM.

13. The method of claim 12 , wherein at the end of the gradient, the elution buffer comprises a sodium chloride concentration of 180 mM.

14. The method of claim 1 , wherein the elution buffer has a pH of from 6 to 9.

15. The method of claim 14 , wherein the elution buffer has a pH of from 7 to 8.

16. The method of claim 15 , wherein the elution buffer has a pH of 7.4±0.2.

17. The method of claim 1 , wherein at the beginning of the gradient the elution buffer comprises 20 mM Tris, 2 mM CaCl 2 , 0.1% Triton X-100, a pH of 7.4±0.2, and a conductivity of 2.11 mS/cm at 25° C.

18. The method of claim 1 , wherein at the end of the gradient the elution buffer comprises 20 mM Tris, 2 mM CaCl 2 , 180 mM sodium chloride, 0.1% Triton X-100, a pH of 7.4±0.2, and a conductivity of 18.6 mS/cm at 25° C.

19. The method of claim 1 , wherein the anion exchange material is a resin comprising a ligand selected from the group consisting of diethylaminoethyl (DEAE), quarternary amionethyl (QAE), quarternary ammonium (Q), polyethyleneimine (PEI), triethlaminoethyl (TMAE), and dimethylaminoethyl (DMAE).

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 31, 2021
From: BAXALTA GMBH; BAXALTA INCORPORATED
To: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Reel/Frame 055189/0005 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 17, 2015
From: BAXTER HEALTHCARE SA
To: BAXALTA GMBH; BAXALTA INCORPORATED
Reel/Frame 036362/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 17, 2015
From: BAXTER INTERNATIONAL INC.
To: BAXALTA GMBH; BAXALTA INCORPORATED
Reel/Frame 036374/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 20, 2008
From: MITTERER, ARTUR; HASSLACHER, MEINHARD; FIEDLER, CHRISTIAN
To: BAXTER INTERNATIONAL INC.; BAXTER HEALTHCARE S.A.
Reel/Frame 020974/0291 →